{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:30:47Z","timestamp":1776281447749,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["305507"],"award-info":[{"award-number":["305507"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["305507"],"award-info":[{"award-number":["305507"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02609-8","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T17:20:11Z","timestamp":1741454411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Echocardiographic and biomarker characteristics in diabetes, coronary artery disease or both: insights from HOMAGE trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Luca","family":"Monzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatake","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohra","family":"Lamiral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Delles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantxa","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Heymans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Petutschnigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Job A. J.","family":"Verdonschot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G. F.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the HOMAGE \u201cHeart Omics in AGEing\u201d Trial Committees and Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"11","key":"2609_CR1","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1161\/CIRCULATIONAHA.106.623199","volume":"114","author":"M Gheorghiade","year":"2006","unstructured":"Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, Sadowski Z, Golba KS, Prior DL, Rouleau JL, Bonow RO. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114(11):1202\u201313.","journal-title":"Circulation"},{"issue":"9733","key":"2609_CR2","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215\u201322.","journal-title":"Lancet"},{"issue":"8","key":"2609_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.amjhyper.2006.01.005","volume":"19","author":"S Govind","year":"2006","unstructured":"Govind S, Saha S, Brodin LA, Ramesh SS, Arvind SR, Quintana M. Impaired myocardial functional reserve in hypertension and diabetes mellitus without coronary artery disease: searching for the possible link with congestive heart failure in the myocardial doppler in diabetes (MYDID) study II. Am J Hypertens. 2006;19(8):851\u20137.","journal-title":"Am J Hypertens"},{"issue":"Suppl","key":"2609_CR4","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/0168-8227(96)01241-7","volume":"31","author":"SM Factor","year":"1996","unstructured":"Factor SM, Borczuk A, Charron MJ, Fein FS, van Hoeven KH, Sonnenblick EH. Myocardial alterations in diabetes and hypertension. Diabetes Res Clin Pract. 1996;31(Suppl):S133\u2013142.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2609_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ehf2.14465","volume":"11","author":"D Santos-Ferreira","year":"2024","unstructured":"Santos-Ferreira D, Diaz SO, Ferreira JP, Girerd N, Pellicori P, Mariottoni B, Cosmi F, Hazebroek M, Verdonschot JAJ, Cuthbert J, et al. Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial. ESC Heart Fail. 2024;11(1):209\u201318.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2609_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12933-021-01357-9","volume":"20","author":"JAJ Verdonschot","year":"2021","unstructured":"Verdonschot JAJ, Ferreira JP, Pellicori P, Brunner-La Rocca HP, Clark AL, Cosmi F, Cuthbert J, Girerd N, Mariottoni B, Petutschnigg J, et al. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovasc Diabetol. 2021;20(1):163.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2609_CR7","doi-asserted-by":"publisher","first-page":"e005897","DOI":"10.1161\/CIRCHEARTFAILURE.118.005897","volume":"12","author":"JP Ferreira","year":"2019","unstructured":"Ferreira JP, Verdonschot J, Collier T, Wang P, Pizard A, Bar C, Bjorkman J, Boccanelli A, Butler J, Clark A, et al. Proteomic bioprofiles and mechanistic pathways of progression to heart failure. Circ Heart Fail. 2019;12(5):e005897.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"2609_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JGF Cleland","year":"2021","unstructured":"Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2021;42(6):684\u201396.","journal-title":"Eur Heart J"},{"key":"2609_CR9","doi-asserted-by":"crossref","unstructured":"Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB, Ricci A. Galectin-3: one molecule for an alphabet of diseases, from a to Z. Int J Mol Sci. 2018;19(2).","DOI":"10.3390\/ijms19020379"},{"key":"2609_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2020.11.002","volume":"57","author":"AC Eddy","year":"2021","unstructured":"Eddy AC, Trask AJ. Growth differentiation factor-15 and its role in diabetes and cardiovascular disease. Cytokine Growth Factor Rev. 2021;57:11\u20138.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"2609_CR11","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/ejhf.2575","volume":"24","author":"P Seferovic","year":"2022","unstructured":"Seferovic P, Farmakis D, Bayes-Genis A, Ben Gal T, Bohm M, Chioncel O, Ferrari R, Filippatos G, Hill L, Jankowska E, et al. Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24(7):1162\u201370.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2609_CR12","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1002\/ehf2.14086","volume":"9","author":"L Monzo","year":"2022","unstructured":"Monzo L, Ferreira JP, Cleland JGF, Pellicori P, Mariottoni B, Verdonschot JAJ, Hazebroek MR, Collier TJ, Cuthbert JJ, Pieske B, et al. Dyskalemia in people at increased risk for heart failure: findings from the heart \u2018OMics\u2019 in AGEing (HOMAGE) trial. ESC Heart Fail. 2022;9(6):4352\u20137.","journal-title":"ESC Heart Fail"},{"issue":"9","key":"2609_CR13","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/ejhf.1716","volume":"22","author":"P Pellicori","year":"2020","unstructured":"Pellicori P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, et al. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The heart OMics in AGing (HOMAGE) trial. Eur J Heart Fail. 2020;22(9):1711\u201323.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2609_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1\u2013e3914.","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"2609_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277\u2013314.","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"2609_CR16","doi-asserted-by":"publisher","first-page":"e0122336","DOI":"10.1371\/journal.pone.0122336","volume":"10","author":"Z Frikha","year":"2015","unstructured":"Frikha Z, Girerd N, Huttin O, Courand PY, Bozec E, Olivier A, Lamiral Z, Zannad F, Rossignol P. Reproducibility in echocardiographic assessment of diastolic function in a population based study (the STANISLAS Cohort study). PLoS ONE. 2015;10(4):e0122336.","journal-title":"PLoS ONE"},{"issue":"4","key":"2609_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"2609_CR18","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","volume":"241","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035\u20138.","journal-title":"JAMA"},{"issue":"2","key":"2609_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","volume":"3","author":"A Dei Cas","year":"2015","unstructured":"Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. 2015;3(2):136\u201345.","journal-title":"JACC Heart Fail"},{"issue":"4","key":"2609_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.cardiores.2004.05.001","volume":"63","author":"G Basta","year":"2004","unstructured":"Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63(4):582\u201392.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2609_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","volume":"8","author":"Y Li","year":"2023","unstructured":"Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K, Huang L, Liu Y. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduct Target Ther. 2023;8(1):152.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2609_CR22","doi-asserted-by":"publisher","first-page":"101265","DOI":"10.1016\/j.diabet.2021.101265","volume":"48","author":"G Lemesle","year":"2022","unstructured":"Lemesle G, Puymirat E, Bonello L, Simon T, Steg PG, Ferrieres J, Schiele F, Fauchier L, Henry P, Schurtz G, et al. Compared impact of diabetes on the risk of heart failure from acute myocardial infarction to chronic coronary artery disease. Diabetes Metab. 2022;48(1):101265.","journal-title":"Diabetes Metab"},{"issue":"6","key":"2609_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/CIRCRESAHA.119.312321","volume":"126","author":"AJ Mouton","year":"2020","unstructured":"Mouton AJ, Li X, Hall ME, Hall JE. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation. Circ Res. 2020;126(6):789\u2013806.","journal-title":"Circ Res"},{"issue":"2","key":"2609_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/ehf2.13174","volume":"8","author":"TD Trippel","year":"2021","unstructured":"Trippel TD, Mende M, Dungen HD, Hashemi D, Petutschnigg J, Nolte K, Herrmann-Lingen C, Binder L, Hasenfuss G, Pieske B, et al. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study. ESC Heart Fail. 2021;8(2):829\u201341.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"2609_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","volume":"11","author":"MY Donath","year":"2011","unstructured":"Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98\u2013107.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2609_CR26","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1210\/jc.2009-1619","volume":"95","author":"J Weigert","year":"2010","unstructured":"Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, Schnitzbauer A, Schaffler A, Aslanidis C, Scholmerich J, Buechler C. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab. 2010;95(3):1404\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"2609_CR27","doi-asserted-by":"publisher","first-page":"868372","DOI":"10.3389\/fcvm.2022.868372","volume":"9","author":"N Zhu","year":"2022","unstructured":"Zhu N, Zhu L, Huang B, Xiang W, Zhao X. Galectin-3 inhibition ameliorates Streptozotocin-Induced Diabetic Cardiomyopathy in mice. Front Cardiovasc Med. 2022;9:868372.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"2609_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.tips.2023.06.001","volume":"44","author":"S Bouffette","year":"2023","unstructured":"Bouffette S, Botez I, De Ceuninck F. Targeting galectin-3 in inflammatory and fibrotic diseases. Trends Pharmacol Sci. 2023;44(8):519\u201331.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"2609_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1530\/EJE-09-0417","volume":"161","author":"I Dostalova","year":"2009","unstructured":"Dostalova I, Roubicek T, Bartlova M, Mraz M, Lacinova Z, Haluzikova D, Kavalkova P, Matoulek M, Kasalicky M, Haluzik M. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol. 2009;161(3):397\u2013404.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2609_CR30","doi-asserted-by":"publisher","first-page":"H118","DOI":"10.1152\/ajpheart.00932.2010","volume":"300","author":"EJ Anderson","year":"2011","unstructured":"Anderson EJ, Rodriguez E, Anderson CA, Thayne K, Chitwood WR, Kypson AP. Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways. Am J Physiol Heart Circ Physiol. 2011;300(1):H118\u2013124.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"16","key":"2609_CR31","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jacc.2009.04.074","volume":"54","author":"LJ Rijzewijk","year":"2009","unstructured":"Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009;54(16):1524\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2609_CR32","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1161\/CIRCULATIONAHA.112.129437","volume":"126","author":"TJ Wang","year":"2012","unstructured":"Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, Ho JE, Fradley MG, Ghorbani A, Xanthakis V, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012;126(13):1596\u2013604.","journal-title":"Circulation"},{"issue":"6","key":"2609_CR33","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s00125-022-05678-6","volume":"65","author":"JB Echouffo-Tcheugui","year":"2022","unstructured":"Echouffo-Tcheugui JB, Daya N, Ndumele CE, Matsushita K, Hoogeveen RC, Ballantyne CM, Coresh J, Shah AM, Selvin E. Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study. Diabetologia. 2022;65(6):955\u201363.","journal-title":"Diabetologia"},{"issue":"6","key":"2609_CR34","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.amjcard.2014.06.020","volume":"114","author":"A Dominguez-Rodriguez","year":"2014","unstructured":"Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2014;114(6):890\u20134.","journal-title":"Am J Cardiol"},{"issue":"17","key":"2609_CR35","doi-asserted-by":"publisher","first-page":"e012826","DOI":"10.1161\/JAHA.119.012826","volume":"8","author":"J Wang","year":"2019","unstructured":"Wang J, Wei L, Yang X, Zhong J. Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. J Am Heart Assoc. 2019;8(17):e012826.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2609_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12944-022-01667-1","volume":"21","author":"Y Mei","year":"2022","unstructured":"Mei Y, Zhao Z, Lyu Y, Li Y. Circulating growth differentiation factor 15 levels and apolipoprotein B to apolipoprotein A1 ratio in coronary artery disease patients with type 2 diabetes mellitus. Lipids Health Dis. 2022;21(1):59.","journal-title":"Lipids Health Dis"},{"key":"2609_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3576","author":"L Monzo","year":"2025","unstructured":"Monzo L, Xhaard C, Ferreira JP, Baudry G, Lamiral Z, Duarte K, Bozec E, Boivin JM, Huttin O, Rossignol P, Zannad F, Girerd N. Circulating growth differentiation factor-15 levels are associated with early echocardiographic signs of diastolic function impairment in the STANISLAS cohort: a 20-year follow-up study. Eur J Heart Fail. 2025. https:\/\/doi.org\/10.1002\/ejhf.3576.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2609_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jchf.2024.10.023","volume":"13","author":"L Monzo","year":"2025","unstructured":"Monzo L, Jarolim P, Borlaug BA, Benes J, Jurcova I, Jenca D, Kroupova K, Wohlfahrt P, Kotrc M, Melenovsky V. Growth differentiation factor-15 is associated with congestion-related anorexia and weight loss in advanced heart failure. JACC Heart Fail. 2025;13(2):315\u201329. https:\/\/doi.org\/10.1016\/j.jchf.2024.10.023.","journal-title":"JACC Heart Fail"},{"issue":"7","key":"2609_CR39","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/echo.15628","volume":"40","author":"L Askin","year":"2023","unstructured":"Askin L, Yuce EI, Tanriverdi O. Myocardial performance index and cardiovascular diseases. Echocardiography. 2023;40(7):720\u20135.","journal-title":"Echocardiography"},{"issue":"4","key":"2609_CR40","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jacc.2009.12.003","volume":"55","author":"AM From","year":"2010","unstructured":"From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 2010;55(4):300\u20135.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2609_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jcmg.2021.07.004","volume":"15","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi M, Huttin O, Magnusson M, Ferreira JP, Bozec E, Huby AC, Preud\u2019homme G, Duarte K, Lamiral Z, Dalleau K, et al. Machine learning-derived echocardiographic phenotypes predict heart failure incidence in asymptomatic individuals. JACC Cardiovasc Imaging. 2022;15(2):193\u2013208.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2609_CR42","doi-asserted-by":"crossref","unstructured":"Tromp J, Khan MA, Klip IT, Meyer S, de Boer RA, Jaarsma T, Hillege H, van Veldhuisen DJ, van der Meer P, Voors AA. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc 2017;6(4).","DOI":"10.1161\/JAHA.116.003989"},{"key":"2609_CR43","doi-asserted-by":"publisher","first-page":"7583690","DOI":"10.1155\/2019\/7583690","volume":"2019","author":"M Mocan","year":"2019","unstructured":"Mocan M, Mocan Hognogi LD, Anton FP, Chiorescu RM, Goidescu CM, Stoia MA, Farcas AD. Biomarkers of inflammation in left ventricular diastolic dysfunction. Dis Markers. 2019;2019:7583690.","journal-title":"Dis Markers"},{"issue":"14","key":"2609_CR44","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jacc.2017.07.792","volume":"70","author":"L Ernande","year":"2017","unstructured":"Ernande L, Audureau E, Jellis CL, Bergerot C, Henegar C, Sawaki D, Czibik G, Volpi C, Canoui-Poitrine F, Thibault H, et al. Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J Am Coll Cardiol. 2017;70(14):1704\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2609_CR45","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jacc.2006.07.033","volume":"48","author":"M Galderisi","year":"2006","unstructured":"Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006;48(8):1548\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2609_CR46","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.cell.2019.07.033","volume":"178","author":"HH Luan","year":"2019","unstructured":"Luan HH, Wang A, Hilliard BK, Carvalho F, Rosen CE, Ahasic AM, Herzog EL, Kang I, Pisani MA, Yu S, et al. GDF15 is an inflammation-Induced central mediator of tissue tolerance. Cell. 2019;178(5):1231\u2013e12441211.","journal-title":"Cell"},{"issue":"1","key":"2609_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1365-2249.2003.02249.x","volume":"134","author":"K Bendtzen","year":"2003","unstructured":"Bendtzen K, Hansen PR, Rieneck K, Spironolactone\/Arthritis Study G. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol. 2003;134(1):151\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"2609_CR48","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/dom.13519","volume":"21","author":"A Natali","year":"2019","unstructured":"Natali A, Nesti L, Venturi E, Shore AC, Khan F, Gooding K, Gates PE, Looker HC, Dove F, Goncalves I, et al. Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: a nested, case-control study. Diabetes Obes Metab. 2019;21(2):412\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2609_CR49","doi-asserted-by":"publisher","first-page":"15314","DOI":"10.3390\/molecules181215314","volume":"18","author":"MM Ciccone","year":"2013","unstructured":"Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, Iacoviello M, Scicchitano P. A novel cardiac bio-marker: ST2: a review. Molecules. 2013;18(12):15314\u201328.","journal-title":"Molecules"},{"issue":"6","key":"2609_CR50","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1055\/a-1523-7574","volume":"130","author":"MF Faienza","year":"2022","unstructured":"Faienza MF, Scicchitano P, Lamparelli R, Zaza P, Cecere A, Brunetti G, Cortese F, Valente F, Delvecchio M, Giordano P, et al. Vascular and myocardial function in young people with type 1 diabetes mellitus: insulin pump therapy versus multiple daily injections insulin regimen. Exp Clin Endocrinol Diabetes. 2022;130(6):415\u201322.","journal-title":"Exp Clin Endocrinol Diabetes"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02609-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02609-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02609-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T03:28:21Z","timestamp":1741490901000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02609-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2609"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02609-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by all relevant ethics committees and regulatory bodies. All participants provided written informed consent prior to study-specific procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"There is no data of individual persons included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.H. acknowledge the support from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON Arena-PRIME, 2017-18, Double Dosis, 2020-B005; Furthermore, we acknowledge the support of FWO G091018N and FWO G0B5930N to S.H. SH provides independent scientific advice on early development in the field of heart failure for AstraZeneca, Ribocure, and CSL Behring, and its university receives research support from AstraZeneca and CSL Behring. F.Z. reports personal fees from Applied Therapeutics, Bayer, Boehringer, BMS, CVRx, Cardior, Cereno Pharmaceutical, Cellprothera, CEVA, Merck, Novartis, Novo Nordisk, Owkin, Pfizer and Servier, having stock options at G3 Pharmaceuticals and equities at Cereno Pharmaceutical, Cardiorenal and Eshmoun Clinical Research and being the founder of Cardiovascular Clinical Trialists. N.G. reports honoraria from AstraZeneca, Bayer, Boehringer, Lilly, Novartis, NovoNordisk, Roche Diagnostics, NP Medical and Echosens. All other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}